{"pmid":32337328,"pmcid":"PMC7176944","title":"Coronaviruses: A patent dataset report for research and development (R&D) analysis.","text":["Coronaviruses: A patent dataset report for research and development (R&D) analysis.","This work shows a patent database for Coronaviruses that provides an overview of the patenting activity and trends in focused antiviral therapy with the use of triazole based compounds, glycoprotein, and protease inhibitors as possible treatment. The patent data was obtained from Orbit Intelligence Software using a patent family structure to get a big database that could be used for built patent landscape report (PLR), market analysis, technical and competitive intelligence, and monitoring and survey of a new ideas for the treatment of coronavirus diseases. The raw data is reported in four databases, which were classified according to different items: legal status (alive, dead), 1(st) application year (after 2015, 2011-2015, 2006-2010, 2001-2005), and Top 5 International Patents Classifications (IPC). The main players, the investment trend, markets, geographical distribution, technology overview, technologies distribution, and patent citation are showed by this analysed data report.","Data Brief","Machuca-Martinez, Fiderman","Amado, Ruben Camargo","Gutierrez, Oscar","32337328"],"abstract":["This work shows a patent database for Coronaviruses that provides an overview of the patenting activity and trends in focused antiviral therapy with the use of triazole based compounds, glycoprotein, and protease inhibitors as possible treatment. The patent data was obtained from Orbit Intelligence Software using a patent family structure to get a big database that could be used for built patent landscape report (PLR), market analysis, technical and competitive intelligence, and monitoring and survey of a new ideas for the treatment of coronavirus diseases. The raw data is reported in four databases, which were classified according to different items: legal status (alive, dead), 1(st) application year (after 2015, 2011-2015, 2006-2010, 2001-2005), and Top 5 International Patents Classifications (IPC). The main players, the investment trend, markets, geographical distribution, technology overview, technologies distribution, and patent citation are showed by this analysed data report."],"journal":"Data Brief","authors":["Machuca-Martinez, Fiderman","Amado, Ruben Camargo","Gutierrez, Oscar"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337328","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.dib.2020.105551","keywords":["2019-ncov","antiviral therapy","competitive intelligence","glycoprotein","patent analysis","protease inhibitor","triazole"],"e_drugs":["Triazoles"],"topics":["Treatment"],"weight":1,"_version_":1666596532364771329,"score":9.490897,"similar":[{"pmid":32429703,"title":"SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.","text":["SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.","Introduction: Coronavirus has been responsible for several virus outbreaks since 2003, caused by SARS-CoV-1, MERS-CoV, and currently SARS-CoV-2 (COVID-19), the causative agent of coronavirus disease in 2019. COVID-19 has become a global public health emergency because of its high virulence and mortality capacity. This patent review aims to provide an overview of the patents that present possible treatments for SARS-CoV-1, SARS-CoV-2 and MERS-CoV.Areas covered: To treat SARS, MERS and SARS-CoV-2, researchers have filed patents for a number of therapeutic agents. Most of the treatments found were protease inhibitors aimed at proteases such as PLpro, 3CLpro, RNA helicase, and Spike protein, or used monoclonal antibodies and interferons. In addition, the use of Chinese folk medicine and its multitude of medicinal plants with strong antiviral properties was reinforced. Thus, these therapies used in previous epidemics can serve as an aid in the new pandemic by SARS-CoV-2 and be a starting point for new treatments.Expert opinion: The various antiviral alternatives presented in this review offer therapeutic options to fight coronavirus infections. If shown to be effective, these drugs may be extremely important in the current pandemic.","Expert Opin Ther Pat","Nascimento Junior, Jose Adao Carvalho","Santos, Anamaria Mendonca","Quintans-Junior, Lucindo Jose","Walker, Cristiani Isabel Bandero","Borges, Lysandro Pinto","Serafini, Mairim Russo","32429703"],"abstract":["Introduction: Coronavirus has been responsible for several virus outbreaks since 2003, caused by SARS-CoV-1, MERS-CoV, and currently SARS-CoV-2 (COVID-19), the causative agent of coronavirus disease in 2019. COVID-19 has become a global public health emergency because of its high virulence and mortality capacity. This patent review aims to provide an overview of the patents that present possible treatments for SARS-CoV-1, SARS-CoV-2 and MERS-CoV.Areas covered: To treat SARS, MERS and SARS-CoV-2, researchers have filed patents for a number of therapeutic agents. Most of the treatments found were protease inhibitors aimed at proteases such as PLpro, 3CLpro, RNA helicase, and Spike protein, or used monoclonal antibodies and interferons. In addition, the use of Chinese folk medicine and its multitude of medicinal plants with strong antiviral properties was reinforced. Thus, these therapies used in previous epidemics can serve as an aid in the new pandemic by SARS-CoV-2 and be a starting point for new treatments.Expert opinion: The various antiviral alternatives presented in this review offer therapeutic options to fight coronavirus infections. If shown to be effective, these drugs may be extremely important in the current pandemic."],"journal":"Expert Opin Ther Pat","authors":["Nascimento Junior, Jose Adao Carvalho","Santos, Anamaria Mendonca","Quintans-Junior, Lucindo Jose","Walker, Cristiani Isabel Bandero","Borges, Lysandro Pinto","Serafini, Mairim Russo"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32429703","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/13543776.2020.1772231","keywords":["covid-19","cov","mers","sars","coronavirus","treatments"],"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667342288187031552,"score":337.5689},{"pmid":32489027,"title":"[Recent advances in treatment of viral pneumonia using Chinese patent medicine].","text":["[Recent advances in treatment of viral pneumonia using Chinese patent medicine].","Viral pneumonia is caused by a spreading of lung infection caused by respiratory viruses. Some virus infections were found to be highly aggressive, leading to lung inflammation and severe damage in respiratory system with high fatality rate. Currently, there is no effective therapeutic drugs in the clinic. The common clinical symptoms of viral pneumonias include fever, rhinitis, runny nose, nonproductive cough, fatigue, myalgias and headaches after the immune system being tricked by driving cytokines and overactivated immune response induced by cytokine storms. Patients with severe symptoms could get persistent high fever, dysfunctional breathing, consciousness disorders and even respiratory failure, post-inflammatory pulmonary fibrosis, multi-organ damages, shock and so on. Most clinical treatments are used to inhibit virus replication, relieve symptoms, inhibit excessive inflammatory response, regulate immune balance and protect organs. Both applied and basic research demonstrate that Chinese patent medicine has certain anti-viral effects, effectively inhibiting viral pneumonia transiting from mild to severe, rapid relieving of patient symptoms because of their multi-component and multi-target integrated roles. This review has summarized the reports on the treatment of viral pneumonia. Based on the pathogenic characteristics of viral pneumonia, this paper summarizes the diverse roles of the marketed Chinese patent medicine, such as their effects in inhibiting the progress of viral replication and overactivated inflammatory response, regulating immune balance, attenuating pulmonary fibrosis and so forth. Our paper summarizes the advantages of Chinese patient medicine in the treatment of viral pneumonia, based on which improvements of clinical therapy are expected to be made soon.","Zhongguo Zhong Yao Za Zhi","Wang, Tao","Han, Li-Feng","Wang, Yue-Fei","Miao, Lin","Yang, Jian","Zhang, Jun-Hua","Gao, Xiu-Mei","Zhang, Bo-Li","32489027"],"abstract":["Viral pneumonia is caused by a spreading of lung infection caused by respiratory viruses. Some virus infections were found to be highly aggressive, leading to lung inflammation and severe damage in respiratory system with high fatality rate. Currently, there is no effective therapeutic drugs in the clinic. The common clinical symptoms of viral pneumonias include fever, rhinitis, runny nose, nonproductive cough, fatigue, myalgias and headaches after the immune system being tricked by driving cytokines and overactivated immune response induced by cytokine storms. Patients with severe symptoms could get persistent high fever, dysfunctional breathing, consciousness disorders and even respiratory failure, post-inflammatory pulmonary fibrosis, multi-organ damages, shock and so on. Most clinical treatments are used to inhibit virus replication, relieve symptoms, inhibit excessive inflammatory response, regulate immune balance and protect organs. Both applied and basic research demonstrate that Chinese patent medicine has certain anti-viral effects, effectively inhibiting viral pneumonia transiting from mild to severe, rapid relieving of patient symptoms because of their multi-component and multi-target integrated roles. This review has summarized the reports on the treatment of viral pneumonia. Based on the pathogenic characteristics of viral pneumonia, this paper summarizes the diverse roles of the marketed Chinese patent medicine, such as their effects in inhibiting the progress of viral replication and overactivated inflammatory response, regulating immune balance, attenuating pulmonary fibrosis and so forth. Our paper summarizes the advantages of Chinese patient medicine in the treatment of viral pneumonia, based on which improvements of clinical therapy are expected to be made soon."],"journal":"Zhongguo Zhong Yao Za Zhi","authors":["Wang, Tao","Han, Li-Feng","Wang, Yue-Fei","Miao, Lin","Yang, Jian","Zhang, Jun-Hua","Gao, Xiu-Mei","Zhang, Bo-Li"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489027","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.19540/j.cnki.cjcmm.20200312.502","keywords":["2019-ncov","covid-19","immunity","inflammation","pulmonary fibrosis","viral pneumonia","viral replication"],"locations":["Chinese","Chinese","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1668623433742680065,"score":256.86066},{"pmid":32478705,"title":"Bringing Cuban Biotech Research to Bear on COVID-19:All Hands and Minds on Deck.","text":["Bringing Cuban Biotech Research to Bear on COVID-19:All Hands and Minds on Deck.","This MEDICC Review roundtable gathers some of Cuba's top researchers in the fi elds of vaccines and biotechnology, all of whom work in institutions belonging to BioCubaFarma, the umbrella company of Cuban biotech and pharmaceutical R&D, production, distribution and export. Founded in 2012, the company is comprised of 34 enterprises with 61 lines of production and some 20,000 employees. A total of 765 of its products are registered in 53 countries and exported to an-other 50. Its scientists' research has resulted in 2640 patents in Cuba and globally.","MEDICC Rev","Castellanos-Serra, Lila","32478705"],"abstract":["This MEDICC Review roundtable gathers some of Cuba's top researchers in the fi elds of vaccines and biotechnology, all of whom work in institutions belonging to BioCubaFarma, the umbrella company of Cuban biotech and pharmaceutical R&D, production, distribution and export. Founded in 2012, the company is comprised of 34 enterprises with 61 lines of production and some 20,000 employees. A total of 765 of its products are registered in 53 countries and exported to an-other 50. Its scientists' research has resulted in 2640 patents in Cuba and globally."],"journal":"MEDICC Rev","authors":["Castellanos-Serra, Lila"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478705","source":"PubMed","week":"202023|Jun 01 - Jun 07","locations":["Cuba","Cuban","Cuba"],"countries":["Cuba"],"countries_codes":["CUB|Cuba"],"weight":0,"_version_":1668437835195088896,"score":241.01454},{"pmid":32268018,"title":"[Analysis of medication characteristics of traditional Chinese medicine in treating coronavirus disease-19 based on data mining].","text":["[Analysis of medication characteristics of traditional Chinese medicine in treating coronavirus disease-19 based on data mining].","OBJECTIVE: To analysis the medication characteristics of the prescriptions issued via open channel by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine in treating coronavirus disease 2019 (COVID-19). METHODS: We collected the data of traditional Chinese medicine related to treatment plans published by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine from the start of COVID-19 outbreak in Wuhan to February 19, 2020. The frequency analysis, cluster analysis and correlation analysis were performed. RESULTS: The study collected 4 national and 34 regional prevention and treatment plans, 578 items, 84 traditional Chinese formulations, 60 Chinese patent medicines, and 230 Chinese herbs. The high frequently used herbs were Liquorice, Scutellariabaicalensis, Semen armeniacaeamarae, and Gypsum. The commonly used traditional formulations included Maxing Shigan Decoction, Yin Qiao Powder, and Xuanbai Chengqi Decoction. The Chinese patent drugs included Angong Niuhuang Pill, Xuebijing Injection, and Lianhua Qingwen Capsule. The most common paired medications were Ephedra and Semen armeniacaeamarae, Fructusforsythiae and Liquorice. Two core combinations and one novel formula were discovered in the study. CONCLUSIONS: Yin Qiao Powder and Huopo Xialing Decoction are the basic formulations for Weifen syndrome of COVID-19. In addition, Maxing Shigan Decoction, Liang Ge Powder, Qingwen Baidu Decoction and Da Yuan Decoction are the basic formulations for Qifen syndrome of COVID-19. The main medication characteristics are clearing heat, entilating lung, removing toxicity and removing turbidity. It shows that removing toxicity and eliminating evil are the prescription thought in treating epidemic disease of traditional Chinese medicine.","Zhejiang Da Xue Xue Bao Yi Xue Ban","Fan, Tiantian","Chen, Yongcan","Bai, Yu","Ma, Fengqi","Wang, Hengcang","Yang, Yiping","Chen, Jinxu","Lin, Yuqi","32268018"],"abstract":["OBJECTIVE: To analysis the medication characteristics of the prescriptions issued via open channel by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine in treating coronavirus disease 2019 (COVID-19). METHODS: We collected the data of traditional Chinese medicine related to treatment plans published by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine from the start of COVID-19 outbreak in Wuhan to February 19, 2020. The frequency analysis, cluster analysis and correlation analysis were performed. RESULTS: The study collected 4 national and 34 regional prevention and treatment plans, 578 items, 84 traditional Chinese formulations, 60 Chinese patent medicines, and 230 Chinese herbs. The high frequently used herbs were Liquorice, Scutellariabaicalensis, Semen armeniacaeamarae, and Gypsum. The commonly used traditional formulations included Maxing Shigan Decoction, Yin Qiao Powder, and Xuanbai Chengqi Decoction. The Chinese patent drugs included Angong Niuhuang Pill, Xuebijing Injection, and Lianhua Qingwen Capsule. The most common paired medications were Ephedra and Semen armeniacaeamarae, Fructusforsythiae and Liquorice. Two core combinations and one novel formula were discovered in the study. CONCLUSIONS: Yin Qiao Powder and Huopo Xialing Decoction are the basic formulations for Weifen syndrome of COVID-19. In addition, Maxing Shigan Decoction, Liang Ge Powder, Qingwen Baidu Decoction and Da Yuan Decoction are the basic formulations for Qifen syndrome of COVID-19. The main medication characteristics are clearing heat, entilating lung, removing toxicity and removing turbidity. It shows that removing toxicity and eliminating evil are the prescription thought in treating epidemic disease of traditional Chinese medicine."],"journal":"Zhejiang Da Xue Xue Bao Yi Xue Ban","authors":["Fan, Tiantian","Chen, Yongcan","Bai, Yu","Ma, Fengqi","Wang, Hengcang","Yang, Yiping","Chen, Jinxu","Lin, Yuqi"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32268018","source":"PubMed","week":"202015|Apr 06 - Apr 12","locations":["Chinese","Wuhan","Chinese","Chinese","Chinese","Liquorice","Semen","Gypsum","Chinese","Semen","Weifen","Qifen","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138491920056321,"score":229.6593},{"pmid":32391675,"title":"[Analysis of medication characteristics of traditional Chinese medicine in treating COVID-19 based on data mining].","text":["[Analysis of medication characteristics of traditional Chinese medicine in treating COVID-19 based on data mining].","OBJECTIVE: To analysis the medication characteristics of the prescriptions issued via open channel by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine in treating coronavirus disease 2019 (COVID-19). METHODS: We collected the data of traditional Chinese medicine related to treatment plans published by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine from the start of COVID-19 outbreak to February 19, 2020. The frequency analysis, cluster analysis and association analysis were performed. RESULTS: The study collected 4 national and 34 regional prevention and treatment plans, 578 items, 84 traditional Chinese formulations, 60 Chinese patent medicines, and 230 Chinese herbs. The high frequently used herbs were Liquorice, Scutellariabaicalensis, Semen armeniacaeamarae, and Gypsum. The commonly used traditional formulations included Maxing Shigan decoction, Yin Qiao powder, and Xuanbai Chengqi decoction. The Chinese patent drugs included Angong Niuhuang pill, Xuebijing injection, and Lianhua Qingwen capsule. The most common paired medications were Ephedra and Semen armeniacaeamarae, Fructusforsythiae and Liquorice. Two core combinations and one novel formula were discovered in the study. CONCLUSIONS: Yin Qiao powder and Huopo Xialing decoction are the basic formulations for Weifen syndrome of COVID-19. In addition, Maxing Shigan decoction, Liang Ge powder, Qingwen Baidu decoction and Da Yuan decoction are the basic formulations for Qifen syndrome of COVID-19. The main medication characteristics are clearing heat, entilating lung, removing toxicity and removing turbidity. It shows that removing toxicity and eliminating evil are the prescription thought in treating epidemic disease of traditional Chinese medicine.","Zhejiang Da Xue Xue Bao Yi Xue Ban","Fan, Tiantian","Chen, Yongcan","Bai, Yu","Ma, Fengqi","Wang, Hengcang","Yang, Yiping","Chen, Jinxu","Lin, Yuqi","32391675"],"abstract":["OBJECTIVE: To analysis the medication characteristics of the prescriptions issued via open channel by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine in treating coronavirus disease 2019 (COVID-19). METHODS: We collected the data of traditional Chinese medicine related to treatment plans published by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine from the start of COVID-19 outbreak to February 19, 2020. The frequency analysis, cluster analysis and association analysis were performed. RESULTS: The study collected 4 national and 34 regional prevention and treatment plans, 578 items, 84 traditional Chinese formulations, 60 Chinese patent medicines, and 230 Chinese herbs. The high frequently used herbs were Liquorice, Scutellariabaicalensis, Semen armeniacaeamarae, and Gypsum. The commonly used traditional formulations included Maxing Shigan decoction, Yin Qiao powder, and Xuanbai Chengqi decoction. The Chinese patent drugs included Angong Niuhuang pill, Xuebijing injection, and Lianhua Qingwen capsule. The most common paired medications were Ephedra and Semen armeniacaeamarae, Fructusforsythiae and Liquorice. Two core combinations and one novel formula were discovered in the study. CONCLUSIONS: Yin Qiao powder and Huopo Xialing decoction are the basic formulations for Weifen syndrome of COVID-19. In addition, Maxing Shigan decoction, Liang Ge powder, Qingwen Baidu decoction and Da Yuan decoction are the basic formulations for Qifen syndrome of COVID-19. The main medication characteristics are clearing heat, entilating lung, removing toxicity and removing turbidity. It shows that removing toxicity and eliminating evil are the prescription thought in treating epidemic disease of traditional Chinese medicine."],"journal":"Zhejiang Da Xue Xue Bao Yi Xue Ban","authors":["Fan, Tiantian","Chen, Yongcan","Bai, Yu","Ma, Fengqi","Wang, Hengcang","Yang, Yiping","Chen, Jinxu","Lin, Yuqi"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391675","source":"PubMed","week":"202020|May 11 - May 17","locations":["Chinese","Chinese","Chinese","Chinese","Liquorice","Semen","Gypsum","Xuanbai Chengqi","Chinese","Semen","Qifen","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666528580080762880,"score":228.16959}]}